| Literature DB >> 24621061 |
Alessandra Mezzelani, Martina Landini, Francesco Facchiano, Maria Elisabetta Raggi, Laura Villa, Massimo Molteni, Barbara De Santis, Carlo Brera, Anna Maria Caroli, Luciano Milanesi, Anna Marabotti.
Abstract
BACKGROUND: Autism is an increasing neurodevelopmental disease that appears by 3 years of age, has genetic and/or environmental etiology, and often shows comorbid situations, such as gastrointestinal (GI) disorders. Autism has also a striking sex-bias, not fully genetically explainable.Entities:
Keywords: Environmental autism; Gut dysbiosis; Immune system; Sex bias; Xenobiotics
Mesh:
Substances:
Year: 2014 PMID: 24621061 PMCID: PMC4485698 DOI: 10.1179/1476830513Y.0000000108
Source DB: PubMed Journal: Nutr Neurosci ISSN: 1028-415X Impact factor: 4.994
Figure 1The gut microbial composition and development in healthy and autistic children. Asterisks refer to a higher (**) or low abundance (*) of microbial flora in an infant healthy gut. Arrows, instead, indicate the increase (↑) or decrease (↓) of gut microbial components according to C-section, breast or formula feed, ASD. ASD, autism spectrum disorder; C-section, cesarean section. 1Data by Finegold et al.27.
Figure 2Differences between eubiosis (a healthy normal microflora) and dysbiosis establishment and consequences.
Figure 3The critical window for immune vulnerability of children. At about 12 months the maternal protection is disappeared as well as antibodies from breastfeeding (especially in early weaning). On the other hand, the functionality and stability of gut microbiota as well as child's own antibodies formation are not yet reached.
Review analysis of literature regarding the most relevant environmental factors or stressors, associated to ASD
| Environmental factors/stressors | Relevant literature | Study type | Association with: | Main findings | Comments | |
|---|---|---|---|---|---|---|
| ASD | ASD + GI disorders | |||||
| Antibiotics | Sandler | Clinical | Yes | Yes | Short-term improvement after low doses of vancomycin and probiotic therapy in a sub-group of regressive ASD children | Small sample size. The reported improvements waned at follow-up. Further investigations are required |
| Atladóttir | Clinical | No | – | Population-based cohort study reporting no associations for ASD and mild infections, febrile episodes, or the use of antibiotics during pregnancy | Methodological limitations due to self-reported data/incomplete information | |
| Diet and food xenobiotics | Batista | Clinical | No | No | No relevant associations among ASD, celiac disease, and glutein sensitivity | Poor diagnosis for ASD |
| Pennesi and Klein[ | Clinical | Yes | Yes | Effectiveness of glutein/casein free diet in a sub-group of ASD children | Retrospective study | |
| Reichelt | Clinical | Yes | – | Finding of exorphins in urines of ASD children | Further studies are required to strengthen the role of bio-active peptides in ASD | |
| Critchfield | Review | – | – | By comparing GI disorders in ASD and IBD, the supply of probiotics for ameliorating ASD symptoms is strongly encouraged | Need for pre-clinical/clinical trials | |
| Williams | Clinical | Yes | Yes | Insights between human gene expression and gut bacterial community composition. | Small sample size. | |
| Genuis | Clinical | – | Yes | Glutein-free diet effectiveness in a 5-years-old child with ASD and suspected celiac disease | Case report | |
| Cass | Clinical | No | – | Lack of evidence for opioid peptides in urine of male ASD children. No effectiveness for opioids in predicting or monitoring the effects of casein/glutein-free diet | No clinical evaluation for GI disorders in the samples. Further studies are required to validate the effectiveness of casein/glutein-free diet in ASD | |
| Microbial metabolites/end-products | Frye and MacFabe[ | Clinical | Yes | – | Short-chain fatty acids and acetyl-carnitine abnormalities in ASD patients versus controls | Further studies are required to strength the similarity between animal models and ASD and to evaluate the role of microbiota as potential PPA source |
| Mavel | Clinical | Yes | – | Aberrant urine metabolic profiling in ASD children versus controls by [ | Needs for larger sample size | |
| Kuwabara | Clinical | Yes | – | CE-TOFMS revealed aberrant metabolites, associated with oxidative stress and mitochondrial dysfunction, in the plasma of ASD adult males | Only adult males taking into account | |
| Ming | Clinical | Yes | Yes | Altered gut microbial metabolites in urines of ASD children, with a stronger association in patients with GI disorders, suggesting a link between gut-dysbiosis and metabolic perturbances | No differences between ASD patients and controls have been found, by considering gender, diet, and vitamins supplementations. | |
| Kalużna-Czaplińska and Blaszczyk[ | Clinical | – | Yes | High levels of arabinose found in autistic children and positive effects of probiotics in reducing them | No controls evaluated. | |
| MacFabe | Pre-clinical | Yes | – | Effects of propionic acid (PPA) in inducing autistic-like behaviors in male adolescent rats | These findings support further evidences on the effects of PPA in young rodents. Further works are required to validate this model in clinical studies | |
| Shaw[ | Clinical | Yes | – | Higher concentrations of HPHPA in the urine of ASD children, in comparison to aged-matched controls, and in one adult affected by | No clinical evaluation for GI disorders in the samples. No analysis on the ASD stool samples | |
| Yap | Clinical | Yes | – | Urinary metabolic alterations in ASD children versus siblings and controls identified by [ | No evaluation for gut microbiota in ASD samples. | |
| Shaw | Clinical | Yes | – | Positive effect of the antifungal therapy in reducing fungal metabolites in ASD patients | No data reported about GI disorders or the analysis of stool samples | |
| Gut microbiota | Gondalia | Clinical | No | No | Pyrosequencing analysis on ASD patients with and without GI disorders and siblings. No evidences for the involvement of gut dysbiosis in ASD | No evaluation for eukaryotic gut microbiota, viruses, or protozoa as well as for dietary differences among participants. Microbial end-products/metabolites should also be studied in the future |
| Adams | Clinical | – | Yes | Strong correlation with GI disorders and autism severity; lower levels of | No differences for yeasts was reported. | |
| Finegold | Clinical | – | Yes | Positive correlation with the highest levels of | No differences between ASD patients and healthy siblings. No evaluation for the potential diet effects on gut microbiota | |
| Parracho | Clinical | Yes | Yes | Association between the high levels of | No differences found between ASD patients and healthy siblings | |
| Song | Clinical-methodol | Yes | – | Identification with Real-Time PCR of | Small sample size. A comparison group of ASD patients with GI disorders was not included | |
| Finegold | Clinical | – | Yes | Higher levels of | Analysis of both fecal flora and gastric and small-bowel specimens. Small sample size | |
ASD, autism spectrum disorder; GI, gastrointestinal; IBD, intestinal bowel disease; PPA, propionic acid; HPHPA, 3-(3-hydroxyphenyl)-3-hydroxypropionic acid; NMR, nuclear magnetic resonance spectroscopy; CE-TOF-MS, capillary electrophoresis time-of-flight mass spectrometry.
Figure 4Suggested pathogenesis for autism. Genetic/immunological susceptibility and environmental risk factors could enhance gut dysbiosis, leading to an aberrant inflammatory response, to an abnormal production of microbial end-products, and to leaky gut. The latter can enhance mal-absorption of both microbial and exogenous xenobiotics derived from diet. Once absorbed in the bloodstream, all these compounds can affect the normal brain development and function both directly and impairing the immune system: the latter creates a loop, of aberrant gut–brain axis communication that contributes to enhance these aberrant physiological responses. Finally, endogenous or exogenous stressors might have an impact in the development of senses, language, and higher cognitive functions developing and integrating in the first period of life.